Article
mRNA splicing variants: exploiting modularity to outwit cancer therapy.
Cancer research - 1 Sept 2013
Dehm Scott M
Abstract excerpt
Systemic cancer therapy has traditionally exploited vulnerabilities in cancer cells, a strategy which has become more precise with the identification and targeting of driver oncogenes. However, persistent tumor growth due to primary (de novo) or secondary (acquired) resistance limits therapeutic efficacy for many patients. Alternative splicing is important for increasing the diversity of the cellular proteome,...
Topics
Join the communities discussing this publication.